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Cytomegalovirus (CMV) is a genus of the ß-herpes virinae subfamily of Herpesviridae, a double-strand DNA 230-kb virus that produces more than 200 proteins. These proteins are produced in three overlapping phases: immediate early (IE), early, and late (1) . Human infection usually peaks first during childhood and results from both vertical and horizontal transmission after virus shedding in urine and in respiratory secretions. The next peak occurs in young adults, mostly by sexual transmission and 50 to more than 90% of the worldwide population become seropositive for CMV throughout life.
Primary CMV infection is commonly asymptomatic in healthy and immunocompetent individuals but can produce fever, myalgia, pharyngitis, cervical lymphadenopathy, mild hepatitis, and spleen enlargement as a mononucleosis-like illness (2) . After primary infection, CMV is not completely eliminated from the host but remains latent in a variety of tissues, particularly within macrophages, granulocytes and dendritic cell precursors (3) . In contrast, reactivation of the virus with severe clinical symptoms is commonly observed in immunocompromised hosts (4, 5) . Leukopenia, pneumonitis, retinitis, encephalitis, and gastrointestinal problems are frequently observed in these patients.
Reactivation of CMV is not completely understood but a series of mechanisms, which have in common the cAMP and NFκB pathways, are likely to play a role, such as stress, inflammation and some cAMP-elevating drugs. These mechanisms lead to activation of the CMV IE enhancer/promoter that initiates virus replication (6) .
Immunologic control of CMV replication includes several THE RISK FOR CMV REACTIVATION AND  THE RISK FOR CMV REACTIVATION AND  THE RISK FOR CMV REACTIVATION AND  THE RISK FOR CMV REACTIVATION AND  THE RISK FOR CMV REACTIVATION AND  REINFECTION IN TRANSPLANT RECIPIENTS  REINFECTION IN TRANSPLANT RECIPIENTS  REINFECTION IN TRANSPLANT RECIPIENTS  REINFECTION IN TRANSPLANT RECIPIENTS  REINFECTION IN TRANSPLANT RECIPIENTS Transplant recipients usually are immunosuppressed and are at high risk of developing CMV diseases. The risk is associated with the degree of T-cell functional impairment and the mode and magnitude of immunosuppression. The serological CMV status of pretransplant donor and recipient (D/R) also correlates with both the incidence and severity of disease. Seronegative recipients of a CMVpositive organ (D + /R -) will develop primary infection. Despite successful treatment, CMV infection recurs in one third of solid organ recipients (10) . Of note, the secondary consequences of CMV infection are: enhanced susceptibility to post-transplant Epstein Barr virus-related lymphoproliferation (11), acute chronic allograft rejection (12) , and opportunistic infections (4) .
The relationship between the risk for CMV disease and the serologic CMV status of D/R is the reverse in stem cell and bone marrow transplants (BMT). Seronegative recipients of CMV-positive donor bone marrow (D + /R -) are not at higher risk of developing CMV disease, while seropositive recipients of seronegative bone marrow donors (D -/R + ) are at an increased risk for reinfection (13, 14) . The least risk for CMV infections in BMT occurs when both donor and recipient are CMV seronegative pre-transplant (D -/R -) (15) . It is thought that the remaining CMV-specific T cells transferred along with the bone marrow of seropositive (D + ) but not with seronegative (D -) donors confer protection against the recipient's (R + ) own CMV reactivation (14, 16, 17) . The risk of developing CMV disease is also higher for stem cell transplant and BMT recipients from unrelated and haploidentical donors (18, 19) . In this case, the risk for CMVdisease is likely to be linked to the predisposition for graftversus-host-disease complications. Graft-versus-host-disease culminates with T-cell functional impairment, as also does CMV-specific cell immunity (14 Before the era of antiviral drugs the only treatment for CMV infection was reduction of immunosuppression in transplant recipients. The development of drugs able to inhibit the viral DNA polymerase activity (Forscanet), or nucleoside analogues (acyclovir, valganciclovir and ganciclovir) that inhibit the incorporation of dGTP terminating the elongation of viral DNA (20, 21) has led to improved anti-CMV disease therapies.
The prophylaxis strategy, in which all transplant recipients are treated with antiviral drugs before and up to 3 months after transplantation, has significantly decreased the incidence of disease as compared with placebo or no treatment (22) . However, long-term prophylaxis with antiviral drugs is myeloablative and nephrotoxic, and can be associated with delayed CMV-specific T-cell immunity recovery, drug resistance and late-onset CMV disease (9, 23, 24) . Besides, unnecessary treatment of individuals that may not develop disease is not desired. Hence, the role of prophylaxis has been questioned in favor of pre-emptive therapy (25) . This approach involves antiviral drug therapy for patients known to be at risk for active or severe disease on the basis of an epidemiological or biological marker. Instead of being administered to all transplant recipients, anti-CMV drugs can be selectively given to the at-risk population saving costs and reducing toxicity.
Biomarkers able to identify patients at risk of developing CMV disease before the onset of the disease are crucial for preemptive therapy. Early on, shell vial cultures of bronchoalveolar lavage for CMV detection were used as a strategy to identify CMV-positive transplant recipients at risk (26) . The preemptive approach has benefited enormously from advances in CMV diagnosis. The pp65 antigenemia and the widespread application of PCR methodology have provided clinicians with the means of monitoring CMV activity more accurately and to identify groups of patients at risk of developing disease (5, 13, 27) . One weakness of the preemptive therapy, however, is that CMV activity may be detected just before, at the same time as or after the manifestation of disease and the treatment may not be efficient. In addition, CMV viral load is not universally associated with disease and some patients may develop CMV disease without testing positive for CMV (26, 28, 29) . An explanation might be linked to the status of the host's antiviral cellular immunity (30) . As we shall discuss next, there is evidence that the pattern of CMVspecific T-cell immunity is an independent risk factor for CMV disease in transplant recipients (31, 32) .
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The role of T cells in anti-viral immunity has been known for a long time (8) . T lymphocytes are important in the early and late stages of virus infections (7, 33) . Upon viral infection the host responds with both the innate and adaptive arms of the immune system. The adaptive immune response is characterized by activation of viral spe-CMV-specific cellular immunity and transplant recipients www.bjournal.com.br cific T-cell clones that differentiate into effector and memory T cells. Memory T cells play an important role in secondary infections when they quickly differentiate into effector cells promoting faster, stronger and more efficient responses against the infectious agent. In the absence of memory T cells, the host is at risk of developing viral disease and severe clinical symptoms. Over the past 5-10 years, conceptual and technical advances have substantially improved T-cell assays for the determination of the phenotypes and functional signatures of memory and effector T cells. It is now possible to functionally characterize Tcell immunity that might be suitable for both diagnosis and clinical monitoring (30, 34, 35) .
In their landmark paper, Sallusto et al. (36) characterized two phenotypically and functionally distinct memory T cells for both CD4 and CD8 T cells. CCR7 -T cells preferentially secrete cytokines IL-4, IL-5 and IFN-γ, and because they lose the expression of CCR7 (a receptor homing to lymph nodes) are prone to circulate into inflamed tissues, and CCR7 + memory T cells that secrete IL-2 and seed lymph nodes and spleen. They were classified as effector memory T cells (CCR7 -) and central memory T cells (CCR7 + ). CD57, CD62L, CD28, CD27, and CD45RA surface markers have also been used to characterize these distinct memory T-cell subpopulations and the CD45RA + CD27 -T-cell phenotypes are thought to be fully differentiated cells exhibiting shorter telomere length (37, 38) . Loss of CD27 and expression of CD45RA in a varying proportion of CMV-specific CD8 T cells are associated with spontaneous IFN-γ secretion and may be a correlate with in vivo virus activity (38, 39) .
Early studies measured intracellular cytokines in response to CMV viral lysates and revealed percentages of cytokine-secreting T cells in seropositive but not in seronegative individuals (40), though with great variation among the seropositive individuals (41) . A hierarchy of cytokinepositive T cells (TNF-α > IFN-γ > IL-2) can be seen in chronic CMV infection (42, 43) . Interestingly, high TNF-α-secreting cells are also high IFN-γ-producing cells, but this correlation is not observed for IL-2-secreting cells (30) . Indeed, a distinct role in viral immunity related to the ability of T cells to secrete IL-2 and/or IFN-γ has been proposed. The presence of viral specific IFN-γ-secreting cells alone defines an acute infection with a high viral antigen load; conversely, the existence of cells producing IL-2 alone, IFN-γ alone or IL-2 plus IFN-γ correlates with chronic infection with low levels of viral antigen.
Using tetramer conjugated peptide, Bunde et al. (44) have recently suggested that protection from CMV infection is correlated with IE-1-specific but not with pp65-specific CD8 T cells in transplant recipients. However, other studies have shown pp65-specific T cells as independent risk factor for CMV disease and long-term virus control in such patients (16, (45) (46) (47) (48) (49) . Transplant recipients with levels of CMV-specific CD8 + T lymphocytes above 0.2-1 x 10 7 cells per liter do not develop CMV disease (16, 45) .
CD4 T cells, on the other hand, are necessary to initiate and maintain CMV CD8-effector immune response as clearly demonstrated on adoptive cellular immunotherapy (16, 32, 48) .
Functional analysis of the cell immune response appears, however, to be a better biomarker for disease risk than the number of CMV-specific T cells (48, 50) . Quinnan et. al. (8) showed as early as in the 1980's the correlation between the presence of CMV-specific cytotoxic T cells and protection from CMV infection. Absence of lymphocyte proliferation in response to CMV antigens in vitro was another risk factor for disease (31) . Until recently, it has been difficult to assess T-cell functional immunity given the complexity of T-cell manipulation, which involves isolation of mononuclear cells from large volumes of biological specimens and careful storage of viable samples. Thus, there has been limited interest in assessing the use and importance of measuring T-cell function in diagnostic and clinical monitoring settings. However, the possibility of assessing T-cell functionality within just about 6 h directly on a fresh whole blood specimen (42) has increased the interest in studying the CMV-specific immune response as a risk factor for CMV disease in transplant recipients (16, (45) (46) (47) (48) (49) . In parallel, a relatively simple procedure for the isolation, in vitro expansion and transfer of CMV-specific T cells into patients has been pursued as therapy for patients at risk of developing CMV disease (51).
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CMV-specific T cells can be functionally assessed by cytokine and chemokine release, cytotoxic potential and T-cell proliferation. Enzyme-linked immunosorbent spot can enumerate cytokine-secreting CMV-specific T cells upon in vitro stimulation with viral antigens (46, 52) . However, assessment of CMV-specific T-cell function by polychromatic flow cytometry enables simultaneously assessment of several functions, including cytokine secretion (intracellular staining), cytotoxic potential (as measured by perforin expression and degranulation activity) and permits the visualization of proliferating T cells based on the use of a dye, carboxyfluorescein succinimidyl ester. Besides, flow cytometry allows to phenotype the T-cell population responding to the stimulus. Over the past 5 years, there has been great interest in the quantification of cytokine production by flow cytometry, referred to as cytokine V.N. Motta and S.L.R. Martins www.bjournal.com.br flow cytometry, which is now in advanced stages of standardization (53) . Important achievement is the possibility to use fresh whole blood or frozen peripheral blood mononuclear cells, which allows direct processing with minimal manipulation, sample shipment, storage, and latter processing (54) . In addition, 96-well plate-based assays, rather than 15-mL tubes, allow high throughput of samples and are suitable for the clinical settings (55) . Moreover, whole blood samples can be processed in 96-deep-well plates (2 mL), in which the entire staining procedure can be performed, including the lysis of red cells, without the need of sample transferring. Stimulation is usually performed for short time, 6-8 h that allows sample collection, processing and analysis on a single day. Besides, automate water bath can be set up to cool samples down to 4°C overnight, by which samples can be processed on the next day (42) .
Briefly, cytokine flow cytometry consists of activating whole blood or peripheral blood mononuclear cells in vitro for 6 h to induce the production of effector cytokines such as IFN-γ or TNF-α. The antigen may be a single peptide or Figure 1 . Figure 1 . Figure 1 . Figure 1 . a pool of peptides (56, 57) , purified virus antigenic polypeptides (58) or even virus-infected cell lysates (43) . The addition of a transport inhibitor such as Brefeldin A prevents secretion and causes cytokine accumulation in the cytoplasm (59) . Then, intracellular cytokine staining is performed and cells are analyzed by flow cytometry (Figure 1 ). This allows a qualitative and quantitative assessment of CMV immunity in patients. Co-staining with CD4, CD8 and MHC-tetramers makes it possible to determine the proportion of tetramer-binding T-cell subsets that respond to stimulation (47) . CD4 T-cell response to CMV is more effective when viral lysates are used, whereas the use of peptides permits a more consistent detection of CD8 T-cell responses (56, 57, 60) . However, protein-spanning pools of overlapping peptides have been shown to stimulate both CD4 and CD8 T-cell responses to CMV in the same sample when peptides of the appropriate length (15 amino acids) and overlap (11 amino acids) are used (57, 60) .
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At present, prophylaxis and preemptive antiviral drug treatment are the most reliable treatment for the prevention of CMV disease in transplant recipients. However, these treatments appear to act as a double-edged sword, leading to a decrease in infection but also to an increase in late-onset drug-resistant CMV disease. Besides, long-term drug treatment has adverse side effects and 5-10% of transplant recipients progress to end-organ CMV disease. Therefore, cell-based immunotherapy and alternative clinical monitoring are desired to manage not only CMV-infected patients but also patients at risk for other viral diseases. The presence of CMV-specific CD4 and CD8 multifunctional T-cell responses indicates efficient control of virus replication. Furthermore, alterations in functional signatures of T cells may detect subtle changes of virus replication activity before detectable levels are reached in the host.
The use of cytokine flow cytometry in clinical settings is expected to be cost-effective. Flow cytometry is already a well-established method widely applied in leukemia diagnosis and immunophenotyping. The costs of cytokine flow cytometry should not be higher than those of other T-cell functional assays, such as the measurement of cell proliferation by thymidine incorporation. In addition, this procedure does not require duplicate or triplicate samples, being very sensitive and specific. The possibility of directly processing whole blood for T-cell stimulation makes the assay less time consuming, with just one additional step in comparison to conventional intracellular leukemia panels, such as TDT, CD3 and immunoglobulin light/heavy chains. Nonetheless, we lack well-designed studies comparing the cost effectiveness of cytokine flow cytometry with other methodologies for monitoring patients at risk of developing CMV disease. Furthermore, standardization of cytokine flow cytometry and well-designed and controlled studies are necessary for a better understanding of the correlation of certain functional T-cell signatures with protection from CMV disease. At present, quantification of IFN-γ-secreting T cells has been associated with risk of developing CMV disease in transplant recipients. However, additional information on distinct T-cell functional signatures might improve diagnosis and deserves further investigation.
In conclusion, functional signatures of T-cell responses can represent sensitive measures of viral activity and may be useful tools for monitoring CMV-associated disease activity in clinical settings.
